Observational Active not recruiting
NCT06294054 on ClinicalTrials.gov
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
Official title: Survival prEdiction in bLadder Cancer Patients Treated by nEoadjuvant Chemotherapy Before cysTectomy
- Sponsor: Hôpital Charles-Nicolle (France)
- Collaborators: Institut Curie
- Enrollment: 707 (Estimated)
- Study start: 2023-04-01 (Actual)
- Primary completion: 2026-03-31 (Estimated)
- Study completion: 2026-03-31 (Estimated)
- Allocation: N/a
- InterventionModel: N/a
- Masking: None
- PrimaryPurpose: Other
Brief Summary
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
Conditions
- Bladder Cancer
- Genomic Instability
Intervention / Treatment
- Combination Product: neoadjuvant chemotherapy with cisplatine
Primary Outcome Measures
-
Progression-free survival
(3 years)
The time from enrollment to progression or death
Countries
France
Locations and Investigators
- Centre de lutte contre le cancer François Baclesse, Caen, France
- Centre de recherche des Cordeliers, Paris, France
- Hôpital Saint-Louis AP-HP, Paris, France
- Institut Curie Centre de Recherche, Paris, France
- Institut Curie, Paris, France
- Institut Gustave Roussy, Paris, France
- Mines ParisTech, Paris, France
Study Officials
- Yves ALLORY, MD (Study Director) — Institut Curie